Please login to the form below

Not currently logged in

Quality in Care anticoagulation programme open for entry

PMGroup's QiC programme aims to recognise best practice in care in the UK

Dr Matthew Fay 

The Quality in Care (QiC) anticoagulation programme is now open for entry to recognise the work carried out by healthcare professionals who improve care for those using anticoagulation therapy in the UK.

The programme is supported in 2015 by Bayer Healthcare, AntiCoagulation Europe (ACE), Stroke Association, Arrhythmia Alliance, Atrial Fibrillation Association and Lifeblood: The Thrombosis Charity.

The awards presentation will be held on September 10 2015 at 30 Euston Square (Royal College of General Practitioners), London. Last year's winners included Dr Matthew Fay (pictured), a GP based near Bradford who picked up the Lifetime Achievement Award.

Other winners included East Kent Hospitals University Foundation Trust, which won Best hospital team of the year; Aneurin Bevan University Health Board and Velindre Cancer Centre, which won Best cross-organisational partnership; and Inspira Health Solutions Ltd and Liverpool Heart and Chest Hospital, which won Anticoagulation innovation of the year.

Annya Stephens-Baol, executive officer at Lifeblood:The Thrombosis Charity, said: “Lifeblood is happy to support the Quality in Care Anticoagulation Programme because it encompasses our objectives of raising awareness of the risks of venous thromboembolism and improving the prevention, management and research of thrombosis.”

The deadline for entries is June 11 and applications can be made at:

Article by
Ben Adams

21st April 2015

From: Healthcare



COVID-19 Updates and Daily News

Featured jobs


Add my company

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Securing a future for telehealth with immersive market research insights...